ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference
Abstracts selected for oral and poster presentations
TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimer’s Association International Conference (AAIC®) to be held July 26-30, 2021 in Denver, USA and online.
ProMIS Chief Scientific Officer, Dr. Neil Cashman will give an oral presentation entitled: “Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.” Dr. Cashman will deliver this presentation and chair the Virtual Oral Session #55269 to be held on Thursday, July 29, from 1:00 PM – 2:15 PM MT.
Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: “Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.” The poster discusses conformational epitopes on misfolded proteins that represent unique targets for therapeutic antibodies. Dr. Kaplan will deliver her poster presentation in person in Denver and online. Please consult the AAIC® website (https://alz.org/aaic/overview.asp) for venue, date and time of the presentation.
Both presentations will be available on the ProMIS website (www.promisneurosciences.com) after the AAIC® closes on July 30.
AAIC® is the largest, most influential international meeting focused on advancing dementia science. The annual conference convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care community to share research discoveries supporting new methods of prevention, treatment and diagnosis of Alzheimer’s disease.
About the ProMIS Pipeline
ProMIS Neurosciences’ lead therapeutic candidate, PMN310, is a monoclonal antibody for Alzheimer’s disease created with a novel, proprietary method for discovering and developing antibodies that can uniquely and precisely target toxic forms of otherwise normal proteins. PMN310 selectively targets the toxic oligomeric species of amyloid beta (Aß), a root cause of Alzheimer’s disease. Preclinical studies show that PMN310 demonstrates a high degree of binding to toxic oligomers as opposed to non-toxic forms of Aß, possessing greater selectivity versus other Aß-directed antibodies. ProMIS has also developed antibody candidates that demonstrate high selectivity for the toxic species of other proteins in the brain, including antibody candidates for Parkinson’s disease that show best-in-class selectivity for toxic forms of alpha-synuclein, and antibody candidates for ALS that selectively target the toxic form of TDP-43.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery platform is based on the use of two complementary thermodynamic, computational discovery engines - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Only 3% of Financial Services Firms Ready for Open Banking Deadline28.7.2021 07:00:00 CEST | Press release
Data Privacy Challenges Blocking Open Banking Adoption for Business Growth, Innovation LONDON, July 28, 2021 (GLOBE NEWSWIRE) -- Only 3% of financial services (FS) organisations are confident they are prepared for the next major Open Banking enforcement deadline, due in September 2021, according to new research from Delphix, the industry leading data company for DevOps. The study – carried out by Pulse and commissioned by Delphix – polled 100 tech leaders in the finance banking and insurance industry to understand how prepared they are for compliance with Open Banking deadlines and what’s getting in the way. All respondents are from EMEA (77%) and APAC (23%) and work at companies with over 10,000 employees. Despite the Second Payments Services Directive (PSD2) and Strong Customer Authentication (SCA) requirement, which were initially slated to take effect September 2019, and then delayed by two years, the majority of FS organisations are still not ready. In fact, according to the poll,
Hexagon Composites ASA: Invitation to presentation of second quarter and half- year results 202128.7.2021 07:00:00 CEST | Press release
Hexagon Composites ASA’s second quarter and half-year results 2021 will be released on 12 August 2021, 07:00 CET. Jon Erik Engeset (CEO) and David Bandele (CFO) will present the results at 08:30 CEST and the presentation will be broadcasted live via https://hexagongroup.kg5.no/ The presentation will be held in English. A recording of the presentation will be made available on www.hexagongroup.com after the presentation. For more information: Hiva Ghiri, VP Investor Relations, Hexagon Composites Telephone: +47 958 66 790 | firstname.lastname@example.org Karen Romer, SVP Communications, Hexagon Composites Telephone: +47 950 74 950 | email@example.com About Hexagon Composites ASA Hexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation, and conversion to clean energy in a wide range of mobility, industrial and consumer applications. Learn more at www.hexagongroup.com and follow @HexagonASA on Twitter and LinkedIn This
Idorsia launches the offering of convertible bonds to fund the development of the company into a leading biopharmaceutical company28.7.2021 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR NOT FOR RELEASE, PUBLICATION, DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS. This announcement is not a prospectus and not an offer of securities for sale in any jurisdiction, including in or into the United States, Japan, Australia or South Africa Idorsia launches the offering of approx. CHF 600 million convertible bonds Allschwil, Switzerland – July 28, 2021 Idorsia Ltd (SIX: IDIA, “Idorsia”) today announced the launch of approx. CHF 600 million senior unsecured convertible bonds (the “Bonds”) due 2028 convertible into shares of Idorsia (the “Shares”). The net proceeds from the offering will be used to support commercial product launches in several key markets in 2022 (pending regulatory approval) and to fund the further development of the company’s advancing late-stage pipeline. Idorsia’s main shareholders, Jean-
Hexagon Purus ASA: Invitation to presentation of second quarter and half- year results 202128.7.2021 07:00:00 CEST | Press release
Hexagon Purus ASA’s second quarter and half-year results 2021 will be released on 10 August 2021, 07:00 CEST. Morten Holum (CEO) and Dilip Warrier (CFO) will present the results at 08:30 CEST and the presentation will be broadcasted live via https://hexagonpurus.kg5.no/ The presentation will be held in English. A recording of the presentation will be made available on www.hexagonpurus.com after the presentation. For more information: Salman Alam, Vice President, Corporate Development, Hexagon Purus ASA Telephone: +47 476 12 713 | firstname.lastname@example.org Dilip Warrier, CFO, Hexagon Purus ASA Telephone: +1 949-236-5528 | email@example.com About Hexagon Purus ASA Hexagon Purus, a Hexagon Composites company, is a world leading provider of hydrogen type 4 high-pressure cylinders, battery packs and vehicle systems integration for fuel cell electric and battery electric vehicles. Hexagon Purus enables zero emission solutions for light, medium and heavy-duty vehicles, buses,
Equinor introduserer første transje av program for tilbakekjøp av aksjer28.7.2021 06:46:00 CEST | Pressemelding
Equinor (OSE: EQNR, NYSE: EQNR) starter i dag første transje på om lag 300 millioner dollar av programmet for tilbakekjøp av aksjer, som ble kunngjort på kapitalmarkedsdagen 15. juni 2021. På kapitalmarkedsdagen kunngjorde Equinor en konkurransedyktig kapitaldistribusjon med en økning av det kvartalsvise kontantutbytte til 18 cent per aksje og oppstart av et nytt program for tilbakekjøp av aksjer, noe som gir en kapitaldistribusjonsstruktur med økt fleksibilitet. Første transje av tilbakekjøpsprogrammet er på inntil 300 millioner USD, inkludert aksjer som innløses fra den norske stat, og vil avsluttes senest 28. september 2021. For 2021 forventes programmet for tilbakekjøp av aksjer å utgjøre om lag 600 millioner USD, inkludert aksjer som innløses fra den norske stat. Fra 2022 forventes et årlig tilbakekjøpsprogram på om lag 1,2 milliarder USD å bli gjennomført når prisen på Brent-olje er i, eller over, prisnivået 50-60 USD/fat, Equinors netto gjeldsgrad(1) holder seg innenfor ambisjon
Equinor commences first tranche in share buy-back programme28.7.2021 06:46:00 CEST | Press release
Equinor (OSE: EQNR, NYSE: EQNR) today commences the first tranche of around USD 300 million, of the new share buy-back programme announced at the Capital Markets Day on 15 June 2021. At the Capital Markets Day Equinor announced a competitive capital distribution with an increase of the quarterly cash dividend to 18 cents per share and the start of a new share buy-back programme, providing a capital distribution structure with increased flexibility. The first tranche of the share buy-back programme is up to USD 300 million, including shares to be redeemed from the Norwegian State, and will end no later than 28 September 2021. For 2021 the share buy-back programme is expected at USD 600 million, including shares to be redeemed from the Norwegian State. Starting in 2022 the annual share buy-back programme of around USD 1.2 billion is expected to be executed when Brent oil prices are in or above the range of 50-60 USD/bbl, Equinor’s net debt ratio(1) stays within the communicated ambition
Equinor ASA: Information relating to dividend for second quarter 202128.7.2021 06:45:00 CEST | Press release
Key information relating to the cash dividend to be paid by Equinor (OSE: EQNR, NYSE: EQNR) for second quarter 2021. Dividend amount: 0.18 Declared currency: USD Last day including rights New York Stock Exchange (NYSE): 9 November 2021 Ex-date NYSE: 10 November 2021 Last day including rights Oslo Børs (Oslo Stock Exchange): 10 November 2021 Ex-date Oslo Børs: 11 November 2021 Record date NYSE and Oslo Børs: 12 November 2021 Payment date: 24 November 2021 Other information: Dividend per share in NOK will be communicated 18 November 2021. This information is published in accordance with the requirements of the Continuing Obligations. This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act